98%
921
2 minutes
20
Objectives: This study hypothesized that left ventricular (LV) enlargement in Barlow disease can be explained by accounting for the total volume load that consists of transvalvular mitral regurgitation (MR) and the prolapse volume.
Background: Barlow disease is characterized by long prolapsing mitral leaflets that can harbor a significant amount of blood-the prolapse volume-at end-systole. The LV in Barlow disease can be disproportionately enlarged relative to MR severity, leading to speculation of Barlow cardiomyopathy.
Methods: Cardiac magnetic resonance (CMR) was used to compare MR, prolapse volume, and heart chambers remodeling in patients with Barlow disease (bileaflet prolapse [BLP]) and in single leaflet prolapse (SLP).
Results: A total of 157 patients (81 with BLP, 76 with SLP) were included. Patients with SLP were older and more had hypertension. Patients with BLP had more heart failure. Indexed LV end-diastolic volume was larger in BLP despite similar transvalvular MR. However, the prolapse volume was larger in BLP, which led to larger total volume load compared with SLP. Increasing tertiles of prolapse volume and MR both led to an incremental increase in LV end-diastolic volume in BLP. Using the total volume load improved the correlation with indexed LV end-diastolic volume in the BLP group, which closely matched that of SLP. A multivariable model that incorporated the prolapse volume explained left heart chamber enlargement better than a MR-based model, independent of prolapse category.
Conclusions: The prolapse volume is part of the total volume load exerted on the LV during the cardiac cycle and could help explain the disproportionate LV enlargement relative to MR severity noted in Barlow disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcmg.2020.08.029 | DOI Listing |
Background: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19.
Methods: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation.
Echocardiography
September 2025
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Aims: Mitral annular disjunction (MAD) has been suggested to be associated with malignant ventricular arrhythmias and sudden cardiac death. Otherwise, left atrial reservoir strain (LARS) has been reported to be useful in predicting risks of cardiovascular events in heart valve diseases. The current study aimed to investigate the relationship between cardiac events and echocardiographic characteristics in patients with Barlow's disease (BD).
View Article and Find Full Text PDFVaccine
August 2025
Department of Infectious Diseases, University College London Hospitals, London, UK; Mortimer Market Centre, Central & Northwest London NHS Foundation Trust, London, UK; The Francis Crick Institute, 1 Midland Road, London, UK; Division of Infection and Immunity, University College London, Gower Stree
Cureus
August 2025
Cardiovascular Surgery, Hokkaido Prefectural Kitami Hospital, Kitami, JPN.
We report a case of totally endoscopic mitral valve repair for severe mitral regurgitation (MR) due to Barlow's disease in a 55-year-old man with severe pulmonary dysfunction following coronavirus disease 2019 (COVID-19) pneumonia. He had developed severe COVID-19 one month earlier, requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO). Although successfully weaned from ECMO, the patient continued to experience persistent fever and was referred to our department for suspected acute MR.
View Article and Find Full Text PDFNeurol Ther
August 2025
Access & Value, Pfizer Japan Inc., Shinjuku Bunka Quint building, 3-22-7, Yoyogi, Shibuya, Tokyo, 151-8589, Japan.
Introduction: Medication overuse headache (MOH) is incurred by the excessive use of acute medications, including over-the-counter (OTC) treatments. This study aimed to characterize the burden, management, and treatment satisfaction of patients with migraine with or without MOH in Japan.
Methods: Data were derived from the Adelphi Migraine Disease Specific Programme (DSP)™, a cross-sectional survey conducted in Japan from August 2023 to February 2024.